The 20-year follow-up report of the Nottingham study of 153 fit elderly patients with ER+ breast cancer < 5 cm, randomized to primary tamoxifen or mastectomy with adjuvant tamoxifen [81], revealed no difference in regional recurrence, metastasis, disease-specific, or overall survival between groups. Here, ESR1 is linked to breast cancer.